MaxCyte Inc (NASDAQ: MXCT) on Friday, plunged -3.09% from the previous trading day, before settling in for the closing price of $2.43. Within the past 52 weeks, MXCT’s price has moved between $2.21 and $5.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 13.60% over the last five years. The company achieved an average annual earnings per share of 8.33%. With a float of $97.96 million, this company’s outstanding shares have now reached $106.31 million.
The firm has a total of 114 workers. Let’s measure their productivity. In terms of profitability, gross margin is 76.18%, operating margin of -132.38%, and the pretax margin is -106.28%.
MaxCyte Inc (MXCT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of MaxCyte Inc is 7.87%, while institutional ownership is 72.61%. The most recent insider transaction that took place on Mar 18 ’25, was worth 3,850. In this transaction Chief Commercial Officer of this company sold 1,211 shares at a rate of $3.18, taking the stock ownership to the 59,439 shares. Before that another transaction happened on Mar 18 ’25, when Company’s GENERAL COUNSEL sold 353 for $3.18, making the entire transaction worth $1,122. This insider now owns 64,219 shares in total.
MaxCyte Inc (MXCT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 8.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.40% during the next five years compared to -11.37% drop over the previous five years of trading.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
MaxCyte Inc (MXCT) is currently performing well based on its current performance indicators. A quick ratio of 11.58 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.40, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of MaxCyte Inc (MXCT)
Analysing the last 5-days average volume posted by the [MaxCyte Inc, MXCT], we can find that recorded value of 1.28 million was better than the volume posted last year of 0.67 million. As of the previous 9 days, the stock’s Stochastic %D was 18.61%. Additionally, its Average True Range was 0.18.
During the past 100 days, MaxCyte Inc’s (MXCT) raw stochastic average was set at 4.85%, which indicates a significant decrease from 9.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.63% in the past 14 days, which was higher than the 60.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.89, while its 200-day Moving Average is $3.77. Now, the first resistance to watch is $2.43. This is followed by the second major resistance level at $2.50. The third major resistance level sits at $2.57. If the price goes on to break the first support level at $2.29, it is likely to go to the next support level at $2.22. Now, if the price goes above the second support level, the third support stands at $2.15.
MaxCyte Inc (NASDAQ: MXCT) Key Stats
Market capitalization of the company is 250.36 million based on 106,319K outstanding shares. Right now, sales total 38,630 K and income totals -41,060 K. The company made 8,690 K in profit during its latest quarter, and -10,600 K in sales during its previous quarter.
